Drugs / Lyophilized herpes zoster virus mRNA vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07400003 | Jan → May 2026 overdue | herpes zoster | Sinovac Biotech Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lyophilized herpes zoster virus mRNA vaccine | “The goal of Part A is to evaluate the safety and preliminary immunogenicity of the lyophilized herpes zoster virus mRNA vaccine (HZ mRNA vaccine) in healthy populations aged 40...” NCT07400003 ↗ |
| Known as | HZ mRNA vaccine | “The goal of Part A is to evaluate the safety and preliminary immunogenicity of the lyophilized herpes zoster virus mRNA vaccine (HZ mRNA vaccine) in healthy populations aged 40...” NCT07400003 ↗ |
| Modality | Messenger RNA (mRNA) | “lyophilized herpes zoster virus mRNA vaccine” NCT07400003 ↗ |